EXSERVAN

PeakSM

riluzole

NDAORALFILM

Approved

Nov 2019

Lifecycle

Peak

Competitive Pressure

30/100

Clinical Trials

15

Mechanism of Action

12.1 Mechanism of Action The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown. 12.2 Pharmacodynamics The clinical pharmacodynamics of riluzole has not been determined in humans. 12.3 Pharmacokinetics Table 2 displays the pharmacokinetic parameters of…

Indications (1)

amyotrophic lateral sclerosis (ALS) ( )

Clinical Trials (5)

NCT06552260Phase 1Recruiting

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Started Feb 2025

27 enrolled

GlioblastomaRecurrent GlioblastomaBrain Tumor

NCT04899921Phase 2Terminated

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Started Jun 2021

1 enrolled

MelanomaMetastatic Melanoma

NCT04708834Phase 3Terminated

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Started Mar 2021

772 enrolled

Obsessive Compulsive Disorder

NCT04641143Phase 3Completed

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Started Dec 2020

456 enrolled

Obsessive-Compulsive Disorder

NCT06529146N/AActive Not Recruiting

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Started Mar 2019

909 enrolled

Spinocerebellar Ataxias

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers